Data from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
Longchuan Bai,Bing Zhou,Chao-Yie Yang,Jiao Ji,Donna McEachern,Sally Przybranowski,Hui Jiang,Jiantao Hu,Fuming Xu,Yujun Zhao,Liu Liu,Ester Fernandez-Salas,Jing Xu,Yali Dou,Bo Wen,Duxin Sun,Jennifer Meagher,Jeanne Stuckey,Daniel F. Hayes,Shunqiang Li,Matthew J. Ellis,Shaomeng Wang
DOI: https://doi.org/10.1158/0008-5472.c.6509556
2023-01-01
Abstract:AbstractTriple-negative breast cancers (TNBC) remain clinically challenging with a lack of options for targeted therapy. In this study, we report the development of a second-generation BET protein degrader, BETd-246, which exhibits superior selectivity, potency, and antitumor activity. In human TNBC cells, BETd-246 induced degradation of BET proteins at low nanomolar concentrations within 1 hour of exposure, resulting in robust growth inhibition and apoptosis. BETd-246 was more potent and effective in TNBC cells than its parental BET inhibitor compound BETi-211. RNA-seq analysis revealed predominant downregulation of a large number of genes involved in proliferation and apoptosis in cells treated with BETd-246, as compared with BETi-211 treatment that upregulated and downregulated a similar number of genes. Functional investigations identified the MCL1 gene as a critical downstream effector for BET degraders, which synergized with small-molecule inhibitors of BCL-xL in triggering apoptosis. In multiple murine xenograft models of human breast cancer, BETd-246 and a further optimized analogue BETd-260 effectively depleted BET proteins in tumors and exhibited strong antitumor activities at well-tolerated dosing schedules. Overall, our findings show that targeting BET proteins for degradation represents an effective therapeutic strategy for TNBC treatment. Cancer Res; 77(9); 2476–87. ©2017 AACR.